A detailed history of Barclays PLC transactions in Biodesix Inc stock. As of the latest transaction made, Barclays PLC holds 23,036 shares of BDSX stock, worth $34,093. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,036
Previous 23,036 -0.0%
Holding current value
$34,093
Previous $41,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$1.53 - $1.96 $32,403 - $41,510
21,179 Added 1140.5%
23,036 $41,000
Q2 2024

Aug 14, 2024

SELL
$1.21 - $1.71 $8,995 - $12,712
-7,434 Reduced 80.01%
1,857 $3,000
Q4 2023

Feb 15, 2024

BUY
$1.2 - $2.13 $11,149 - $19,789
9,291 New
9,291 $17,000
Q2 2023

Aug 03, 2023

BUY
$1.12 - $1.88 $276 - $464
247 New
247 $0
Q2 2022

Aug 12, 2022

SELL
$1.32 - $2.12 $3,016 - $4,844
-2,285 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$1.69 - $5.81 $3,861 - $13,275
2,285 New
2,285 $4,000

Others Institutions Holding BDSX

About BIODESIX INC


  • Ticker BDSX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 39,982,000
  • Market Cap $59.2M
  • Description
  • Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pat...
More about BDSX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.